| Autor: |
Philipp MT; Department of Bacteriology and Parasitology, Tulane National Primate Research Center, Tulane University Health Sciences Center, Covington, LA 70433, USA. Philipp@tpc.tulane.edu, Wormser GP, Marques AR, Bittker S, Martin DS, Nowakowski J, Dally LG |
| Jazyk: |
angličtina |
| Zdroj: |
Clinical and diagnostic laboratory immunology [Clin Diagn Lab Immunol] 2005 Sep; Vol. 12 (9), pp. 1069-74. |
| DOI: |
10.1128/CDLI.12.9.1069-1074.2005 |
| Abstrakt: |
C(6), a Borrelia burgdorferi-derived peptide, is used as the antigen in the C(6)-Lyme disease diagnostic test. We assessed retrospectively whether a fourfold decrease or a decrease to a negative value in anti-C(6) antibody titer is positively correlated with a positive response to treatment in a sample of culture-confirmed patients with either early localized (single erythema migrans [EM]; n=93) or early disseminated (multiple EM; n=27) disease. All of these patients had been treated with antibiotics and were free of disease within 6 to 12 months of follow-up. Results show that a serum specimen taken at this time was either C(6) negative or had a >or=4-fold decrease in C(6) antibody titer with respect to a specimen taken at baseline (or during the early convalescent period if the baseline specimen was C(6) negative) for all of the multiple-EM patients (P<0.0001) and in 89% of the single-EM patients (P<0.0001). These results indicate that a decline in anti-C(6) antibody titer coincides with effective antimicrobial therapy in patients with early localized or early disseminated Lyme borreliosis. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
